Trending Topic

2 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are pleased to present the latest issue of touchREVIEWS in Endocrinology, which offers a timely and thoughtprovoking collection of articles that reflect both the continuity and evolution of diabetes and metabolic disease research. In an era where technology, public health priorities and clinical paradigms are shifting rapidly, this issue highlights the importance of evidence-based […]

Jennifer Green, EASD 2022: Combination effect of finerenone and empagliflozin in participants with chronic kidney disease and type 2 diabetes: The CONFIDENCE Study

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 17th 2022

Finerenone (a selective nonsteroidal mineralocorticoid receptor antagonist) and the SGLT2 inhibitor empagliflozin may reduce both kidney and cardiovascular risks in people with chronic kidney disease and type 2 diabetes. It is unknown whether dual therapy with finerenone and empagliflozin is superior to either agent alone. In this touchENDOCRINOLOGY interview, Prof. Jennifer Green (Duke University School of Medicine, Durham, NC, USA) discusses the design of the CONFIDENCE study which addresses this clinical question. 

The abstract entitled: ‘Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using an UACR Endpoint study (CONFIDENCE) was presented at the European Association for the Study of Diabetes, 19-23 Sept, 2022.

Questions:

  1. What are the aims and design of the CONFIDENCE study? (0:17)
  2. What are the eligibility criteria of the study? (1:37)
  3. What are the primary and secondary outcome measures? (2:30)

Disclosures: Jennifer Green discloses grant/research support from Boehringer Ingelheim/Lilly, Merck and Roche.

Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.

Recorded as a highlight of EASD 2022

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup